Becton Dickinson & Co Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.8%projected annual EPS growth
Analyst Coverage
12analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q4 Fiscal 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Adjusted Gross Margin Quarterly54.7%Target: Expansion driven by BD Excellence initiative
Adjusted Operating Margin Quarterly24.2%Target: ~30% over time
Organic Revenue Growth Quarterly2.6%Target: Mid-single-digit growth (3% to 5%)
Watch Items
- China Volume-Based Procurement (VBP) HeadwindsTrigger: Transitory through 2026, expected to ease in 2027Action: Monitor segment revenue in Life Sciences and Interventional divisions
- Integration of BD Advanced Patient MonitoringTrigger: Synergy realization and margin contribution post-acquisition from Edwards LifesciencesAction: Review quarterly cash flow and operating margin updates
- GLP-1 Biologics Delivery Segment ExpansionTrigger: Targeting $1 billion in annual revenue by 2030Action: Track clinical trial progress and commercial adoption of BD Libertas Wearable Injector
Research as of 2 Sep 2026